ReviewParasite immunology2017
Nematodes and human therapeutic trials for inflammatory disease.
Review in Parasite immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 54 citations in OpenAlex.
- Randomized, Placebo Controlled Trial of Experimental Hookworm Infection for Improving Gluten Tolerance in Celiac Disease.Clinical and translational gastroenterology · 2020Trial
- Hookworm Treatment for Relapsing Multiple Sclerosis: A Randomized Double-Blinded Placebo-Controlled Trial.JAMA neurology · 2020Trial
- In vivo reduction of Treg expansion in rodent helminth-malaria coinfection.Parasites & vectors · 2026Article
- Article
- The parasitic worm product ES-62 protects against collagen-induced arthritis by resetting the gut-bone marrow axis in a microbiome-dependent manner.Frontiers in tropical diseases · 2024Article
- Modulation of LPS-Induced Neurodegeneration by Intestinal Helminth Infection in Ageing Mice.International journal of molecular sciences · 2023Article
- After Bone Marrow Transplantation, the Cell-Intrinsic Th2 Pathway Promotes Recipient T Lymphocyte Survival and Regulates Graft-versus-Host Disease.ImmunoHorizons · 2023Article
- Helminth Lessons in Inflammatory Bowel Diseases (IBD).Biomedicines · 2023Review
- Programmed and environmental determinants driving neonatal mucosal immune development.Immunity · 2023Review
- Ascarosides from helminths pack a punch against allergy.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Immunomodulatory and biological properties of helminth-derived small molecules: Potential applications in diagnostics and therapeutics.Frontiers in parasitology · 2022Review
- The parasitic worm product ES-62 protects the osteoimmunology axis in a mouse model of obesity-accelerated ageing.Frontiers in immunology · 2022Article
- Parasitic Infections of the Gastrointestinal Track and Liver.Gastroenterology clinics of North America · 2021Review
- Immune System Investigation Using Parasitic Helminths.Annual review of immunology · 2021Review
- Review
- Schistosome Infection and Schistosome-Derived Products as Modulators for the Prevention and Alleviation of Immunological Disorders.Frontiers in immunology · 2021Review
- GAS6 signaling tempers Th17 development in patients with multiple sclerosis and helminth infection.PLoS pathogens · 2020Article
- The parasitic worm product ES-62 promotes health- and life-span in a high calorie diet-accelerated mouse model of ageing.PLoS pathogens · 2020Article
- Potential application of helminth therapy for resolution of neuroinflammation in neuropsychiatric disorders.Metabolic brain disease · 2020Review
- Differences in the Clinical and Hematological Characteristics of COVID-19 Patients with and without Type 2 Diabetes.Journal of diabetes research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Helminth infections likely provide a protective influence against some immune-mediated and metabolic diseases because helminth infection dramatically decreased in developed countries shortly before the explosive rise in the prevalence of these diseases. The capacity of helminths to activate immune-regulatory circuits in their hosts and to modulate the composition of intestinal flora appears to be the mechanisms of protective action. Animal models of disease show that various helminth species prevent and/or block inflammation in various organs in a diverse range of diseases. Clinical trials have demonstrated that medicinal exposure to Trichuris suis or small numbers of Necator americanus is safe with minor, if any, reported adverse effects. This includes exposure of inflamed intestine to T. suis, asthmathic lung to N. americanus and in patients with atopy. Efficacy has been suggested in some small studies, but is absent in others. Factors that may have led to inconclusive results in some trials are discussed. To date, there have been no registered clinical trials using helminths to treat metabolic syndrome or its component conditions. However, the excellent safety profile of T. suis or N. americanus suggests that such studies should be possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.